Abstract:
OBJECTIVES:Perceiving the need for rigorous recommendations to facilitate decisions concerning the management of patients with multiple myeloma (MM), the Italian Society of Hematology (SIE) and the two affiliate societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of MM using evidence-based knowledge and consensus formation techniques. METHODS:After a comprehensive systematic review of 1,450 papers, an Expert Panel formulated and graded sixty recommendations according to the supporting evidence. Evidence gaps were filled with twenty-two consensus-based statements. High grade recommendations (grade A) are reported below. RESULTS:Treatment should be immediately initiated in MM patients with related organ damage: those patients aged below 65 years who do not have severe co-morbidities should receive autologous stem cell transplantation, while patients not candidates for autologous stem cell transplantation should receive oral melphalan and prednisone. Interferon-a should not be associated with conventional chemotherapy, but it can be offered with or without steroids as a maintenance therapy to patients who have reached a plateau phase. High-dose dexamethasone-containing regimens or high-dose dexamethasone alone are recommended as a first-line therapy when cytoreduction is urgently required (i.e., MM with spinal cord compression or with rapidly progressive renal failure). MM patients with moderate-to-severe anemia should receive erythropoietin, while patients with bone disease or osteopenia should receive long-term bisphophonates. Recommendations for the management of the clinical manifestations caused by the monoclonal protein (i.e. hyperviscosity, cast nephropathy, AL amyloidosis) and of solitary bone and extramedullary plasmacytoma were also elaborated. CONCLUSIONS:A substantial proportion of clinical care for MM can be guided by evidence-based treatment recommendations.
journal_name
Haematologicajournal_title
Haematologicaauthors
Barosi G,Boccadoro M,Cavo M,Corradini P,Marchetti M,Massaia M,Merlini G,Tosi P,Tura S,Italian Society of Hematology.,Italian Society of Experimental Hematology.,Italian Group for Bone Marrow Transplantation.keywords:
subject
Has Abstractpub_date
2004-06-01 00:00:00pages
717-41issue
6eissn
0390-6078issn
1592-8721journal_volume
89pub_type
杂志文章,实务指引,评审相关文献
HAEMATOLOGICA文献大全abstract::Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells ex...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2014.111740
更新日期:2015-02-01 00:00:00
abstract::Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unknown. To address this...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.098608
更新日期:2014-07-01 00:00:00
abstract::Second central nervous system (CNS) relapses represent about 7.3% of subsequent recurrences of childhood acute lymphoblastic leukemia (ALL). In most children these subsequent CNS relapses occur during the first 18 months after diagnosis of the first relapse (mean 1.42 +/- 0.73 years). We present a patient who suffered...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2004-07-01 00:00:00
abstract::Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). However, whether these thrombophilic abnormalities are also risk factors for recurrent VTE is unclear. We conducted a systematic review of p...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:10.3324/haematol.10234
更新日期:2007-08-01 00:00:00
abstract:BACKGROUND:Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare th...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2009.019042
更新日期:2011-01-01 00:00:00
abstract::In this open label pilot safety study 80 children over 3 months old with deep venous thrombosis were treated with enoxaparin with a target 4 h anti-factor Xa activity between 0.5-0.8 IU/mL. The children were stratified to receive once daily or twice daily doses. The study end-points were post-thrombotic syndrome, re-t...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:
更新日期:2006-12-01 00:00:00
abstract:BACKGROUND:Many different techniques have been designed for the quantification of JAK2V617F allelic burden, sometimes producing discrepant results. DESIGN AND METHODS:JAK2V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specif...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.13486
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Allogeneic stem cell transplantation is a potentially curative treatment for myelofibrosis, although its use is limited by a high rate of transplant-related mortality. In this study, we evaluated the outcome of patients with myelofibrosis who underwent allogeneic stem cell transplantation, and the impact of ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12828
更新日期:2008-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients affected by hereditary bleeding disorders and treated with non-virus inactivated clotting factor concentrates during the 1970s. INFORMATION SOURCES:In this review, we briefly report the present know...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:
更新日期:2002-05-01 00:00:00
abstract::Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.2015.141622
更新日期:2016-07-01 00:00:00
abstract::The occurrence of immunoglobulin heavy chain (IgH) and/or T-cell receptor (TcR) gene rearrangements has been reported in some cases of acute non lymphoid leukemia (ANLL), and variously interpreted as reflecting "aberrant gene expression" or "lineage promiscuity" of the leukemic cell. In an attempt to verify the incide...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1990-03-01 00:00:00
abstract::The mouse pro-B cell line Ba/F3 has gained major interest as a model system to investigate oncogenic tyrosine kinases and to determine the efficacy of kinase inhibitors. While Ba/F3 cells are suitable to study oncogenic kinases derived from various cell types, the signaling networks in Ba/F3 cells are B-cell specific....
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.035931
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:We investigated outcomes in a UK neonatal cohort as a benchmark for care of children with sickle cell disease (SCD). DESIGN AND METHODS:Two-hundred and fifty-two children (180 with hemoglobin [Hb] SS, 64 with HbSC, and 8 with HbS/beta thalassemia), identified during 1983-2005 by universal bir...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.10937
更新日期:2007-07-01 00:00:00
abstract::Suspicion of myelodysplastic syndromes (MDS) is one of the commonest reasons for bone marrow aspirate in elderly patients presenting with persistent peripheral blood (PB) cytopenia of unclear etiology. A PB assay that accurately rules out MDS would have major benefits. The diagnostic accuracy of the intra-individual r...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2018.202275
更新日期:2019-12-01 00:00:00
abstract::As in other malignancies, peripheral blood progenitor cells (PBPC) have almost completely replaced bone marrow as the source of stem cells for autologous transplantation in multiple myeloma. PBPC collection could be optimized either by reducing contamination by the malignant clone or by increasing hematopoietic qualit...
journal_title:Haematologica
pub_type: 临床试验,杂志文章,随机对照试验,评审
doi:
更新日期:1999-06-01 00:00:00
abstract::Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complet...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2004-05-01 00:00:00
abstract:BACKGROUND:We have previously shown that bortezomib induces a depletion of alloreactive T cells and allows the expansion of T cells with suppressive properties. In the current study, we analyzed the potential synergistic effect of bortezomib in conjunction with sirolimus in order to reduce-graft-versus-host disease wit...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2011.058677
更新日期:2012-09-01 00:00:00
abstract::Tumor microenvironment (TME) and limited immune surveillance play important roles in lymphoma pathogenesis. Here, we aimed to characterize immunological profiles of diffuse large B-cell lymphoma (DLBCL), and predict the outcome in response to immunochemotherapy. We profiled the expression of 730 immune-related genes i...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2019.243626
更新日期:2020-02-20 00:00:00
abstract::It is well known that thalassemic patients exhibit an increased frequency of thrombotic events. Most individuals with resistance to activated protein C (APCR) are the result of a point mutation replacing Arg 506 with Gln in the factor V aminoacidic sequence (factor V Leiden). Recently APCR has been shown to account fo...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1997-11-01 00:00:00
abstract::Forty-six patients with chronic myeloid leukemia receiving imatinib mesylate (39 in chronic phase, one in accelerated phase, and six in blastic crisis), were studied for a 20-62 month follow-up period by cytogenetics and fluorescence in situ hybridization using dual-color, dual-fusion BCR and ABL probes. This approach...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2006-07-01 00:00:00
abstract::Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected. Chronic graft-versus-host disease is an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. This a...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.13311
更新日期:2008-11-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Patients with acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome and abnormalities of megakaryocytopoiesis often have cytogenetic aberrations of 3q21 and 3q26 bands involving the paracentric inversion [inv(3) (q21q26)] or a reciprocal translocation [t(3;3) (q21;q26)]. ...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2003-11-01 00:00:00
abstract::Not available. ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2020.266320
更新日期:2021-01-28 00:00:00
abstract:BACKGROUND AND OBJECTIVE:The outcome of patients with severe aplastic anemia (SAA) has improved considerably over the last decades. Bone marrow transplantation (BMT) is the treatment of choice in young patients who have an HLA-identical sibling donor. This study analyzes the outcome and factors related to survival in p...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1999-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Hemoglobin Constant Spring (Hb CS), caused by a termination codon mutation (TAA-->CAA) in the a2 gene, is the most common non-deletional type of a thalassemia in Southeast Asia. This mutation can most easily be detected by loss of an MseI-restriction site (T/TAA) spanning the termination codon...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2002-02-01 00:00:00
abstract::A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point s...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.103218
更新日期:2014-06-01 00:00:00
abstract::Plasma levels of several soluble factors were assayed in 31 untreated patients with high-grade non-Hodgkin's lymphomas (NHL). The results showed statistically significant higher average levels of interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-2 receptor (IL-2r) and transferrin receptor (...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1992-11-01 00:00:00
abstract::Juvenile hemochromatosis is a severe form of hereditary iron overload. It can be caused by mutations in either hepcidin or hemojuvelin genes. In this study we identified the molecular basis of juvenile hemochromatosis in three Australian families and assessed the role of potential modifying genes in individuals carryi...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2005-02-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to be related to disease stage, duratiion of disease and type of donor. Furthermore, the outcome of transplants performed in the 1990s appears to be better than that of tran...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2004-10-01 00:00:00
abstract:BACKGROUND:Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone. DESIGN AND METHODS:In this prospective, multicenter, phase II study, patients with relapsed/refractory mantle cell lymphoma who were not eligible for, or had relap...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.2011.051813
更新日期:2012-03-01 00:00:00